Anastrazole 120511-73-1
-
Post Date:
May 07,2019
-
Expiry Date:
Nov 03,2019
-
Detailed Description:
Cas No. :120511-73-1
Anastrozole (INN) is a non-steroidal aromatase-inhibiting drug approved for treatment of breast cancer after surgery, as well as for metastasis in both pre and post-menopausal women. The severity of breast cancer can be increased by estrogen, as sex hormones cause hyperplasia, and differentiation at estrogen receptor sites. Anastrozole works by inhibiting the synthesis of estrogen.
-
CAS Registry Number:
120511-73-1
-
Synonyms:
;Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-benzenediacetionitrile;ICI-D-1033;Arimidex;1-[3,5-DI-(1-METHYL-1-CYANO)-ETHYL]-BENZYL-1,2,4-TRIAZOLE;ANASTRAZOLE;tetramethyl-5-(1h-1,2,4-triazol-1ylmethyl) 1,3-benzenediacetionitrile;ZD-1033;1,3-benzenediacetonitrile,alpha,alpha,alpha',alpha'-tetramethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-;Anastrozol;Anatrozole;ZD-1033, ICI-D-1033, Arimidex;2-[3-(2-Cyano-2-propyl)-5-(1,2,4-triazol-1-ylmethyl)phenyl]-2-methylpropiononitrile;1,3-benzenediacetonitrile, alpha,alpha,alpha',alpha'-tetramethyl- 5-(1h-1,2,4-triazol-1-ylmethyl)-
zd;1,3-Benzenediacetonitrile,a,a,a',a'-tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl);2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile);
-
Molecular Formula:
C17H19N5
-
Molecular Weight:
293.37
-
Molecular Structure:
Inquiry